MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ
2.620
+0.020
+0.77%
Opening 14:01 08/20 EDT
OPEN
2.540
PREV CLOSE
2.600
HIGH
2.620
LOW
2.540
VOLUME
6.26K
TURNOVER
--
52 WEEK HIGH
2.990
52 WEEK LOW
1.765
MARKET CAP
11.59M
P/E (TTM)
-1.0597
1D
5D
1M
3M
1Y
5Y
1D
Kiora Licenses KIO-301 Rights in South Korea
TipRanks · 1d ago
Weekly Report: what happened at KPRX last week (0810-0814)?
Weekly Report · 3d ago
Weekly Report: what happened at KPRX last week (0803-0807)?
Weekly Report · 08/10 10:19
Analysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)
TipRanks · 08/08 16:30
Kiora Pharmaceuticals GAAP EPS of -$0.34 beats by $0.28
Seeking Alpha · 08/07 11:27
Weekly Report: what happened at KPRX last week (0727-0731)?
Weekly Report · 08/03 10:18
Weekly Report: what happened at KPRX last week (0720-0724)?
Weekly Report · 07/27 10:23
Weekly Report: what happened at KPRX last week (0713-0717)?
Weekly Report · 07/20 10:19
More
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Webull offers Kiora Pharmaceuticals Inc stock information, including NASDAQ: KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.